Crossmark

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide

Crossref DOI link: https://doi.org/10.1186/s13104-018-3453-z

Published Online: 2018-05-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakai, Yasushi

Tanaka, Nobumichi

Miyake, Makito

Inoue, Takeshi

Anai, Satoshi

Fujimoto, Kiyohide
License Information

Text and Data Mining valid from 2018-05-29
More Information

Article History

Received: 25 April 2018

Accepted: 24 May 2018

First Online: 29 May 2018